Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 278

1.

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.

Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang JC, Sanders ME, Cook RS, Arteaga CL.

Sci Transl Med. 2016 Apr 13;8(334):334ra53. doi: 10.1126/scitranslmed.aad3001.

PMID:
27075627
2.

Early and multiple origins of metastatic lineages within primary tumors.

Zhao ZM, Zhao B, Bai Y, Iamarino A, Gaffney SG, Schlessinger J, Lifton RP, Rimm DL, Townsend JP.

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2140-5. doi: 10.1073/pnas.1525677113. Epub 2016 Feb 8.

PMID:
26858460
3.

Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial.

Bartlett JM, Christiansen J, Gustavson M, Rimm DL, Piper T, van de Velde CJ, Hasenburg A, Kieback DG, Putter H, Markopoulos CJ, Dirix LY, Seynaeve C, Rea DW.

Arch Pathol Lab Med. 2016 Jan;140(1):66-74. doi: 10.5858/arpa.2014-0599-OA.

PMID:
26717057
4.

miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.

Adams BD, Wali VB, Cheng CJ, Inukai S, Booth CJ, Agarwal S, Rimm DL, Győrffy B, Santarpia L, Pusztai L, Saltzman WM, Slack FJ.

Cancer Res. 2016 Feb 15;76(4):927-39. doi: 10.1158/0008-5472.CAN-15-2321. Epub 2015 Dec 16.

PMID:
26676753
5.

Loss of antigenicity with tissue age in breast cancer.

Combs SE, Han G, Mani N, Beruti S, Nerenberg M, Rimm DL.

Lab Invest. 2016 Mar;96(3):264-9. doi: 10.1038/labinvest.2015.138. Epub 2015 Nov 16.

PMID:
26568292
6.

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.

McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL.

JAMA Oncol. 2016 Jan;2(1):46-54. doi: 10.1001/jamaoncol.2015.3638. Erratum in: JAMA Oncol. 2016 Jan;2(1):146.

PMID:
26562159
7.

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.

Clin Cancer Res. 2016 Mar 15;22(6):1499-509. doi: 10.1158/1078-0432.CCR-15-1125. Epub 2015 Oct 29.

PMID:
26515496
8.

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.

Wilson MA, Zhao F, Khare S, Roszik J, Woodman SE, D'Andrea K, Wubbenhorst B, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KL.

Clin Cancer Res. 2016 Jan 15;22(2):374-82. doi: 10.1158/1078-0432.CCR-15-1162. Epub 2015 Aug 25.

PMID:
26307133
9.

Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.

Carvajal-Hausdorf DE, Schalper KA, Pusztai L, Psyrri A, Kalogeras KT, Kotoula V, Fountzilas G, Rimm DL.

J Natl Cancer Inst. 2015 May 19;107(8). pii: djv136. doi: 10.1093/jnci/djv136. Print 2015 Aug.

PMID:
25991002
10.

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.

Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB.

Clin Cancer Res. 2015 Jul 1;21(13):3052-60. doi: 10.1158/1078-0432.CCR-14-3073. Epub 2015 Mar 18.

PMID:
25788491
11.

Expertise vs evidence in assessment of breast biopsies: an atypical science.

Davidson NE, Rimm DL.

JAMA. 2015 Mar 17;313(11):1109-10. doi: 10.1001/jama.2015.1945. No abstract available.

PMID:
25781438
12.

Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies.

Jeon YJ, Khelifa S, Ratnikov B, Scott DA, Feng Y, Parisi F, Ruller C, Lau E, Kim H, Brill LM, Jiang T, Rimm DL, Cardiff RD, Mills GB, Smith JW, Osterman AL, Kluger Y, Ronai ZA.

Cancer Cell. 2015 Mar 9;27(3):354-69. doi: 10.1016/j.ccell.2015.02.006.

13.

Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer.

Blume-Jensen P, Berman DM, Rimm DL, Shipitsin M, Putzi M, Nifong TP, Small C, Choudhury S, Capela T, Coupal L, Ernst C, Hurley A, Kaprelyants A, Chang H, Giladi E, Nardone J, Dunyak J, Loda M, Klein EA, Magi-Galluzzi C, Latour M, Epstein JI, Kantoff P, Saad F.

Clin Cancer Res. 2015 Jun 1;21(11):2591-600. doi: 10.1158/1078-0432.CCR-14-2603. Epub 2015 Mar 2.

PMID:
25733599
14.

Objective measurement and clinical significance of TILs in non-small cell lung cancer.

Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL.

J Natl Cancer Inst. 2015 Feb 3;107(3). pii: dju435. doi: 10.1093/jnci/dju435. Print 2015 Mar.

15.

Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.

Kunstman JW, Juhlin CC, Goh G, Brown TC, Stenman A, Healy JM, Rubinstein JC, Choi M, Kiss N, Nelson-Williams C, Mane S, Rimm DL, Prasad ML, Höög A, Zedenius J, Larsson C, Korah R, Lifton RP, Carling T.

Hum Mol Genet. 2015 Apr 15;24(8):2318-29. doi: 10.1093/hmg/ddu749. Epub 2015 Jan 9.

16.

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.

Wimberly H, Brown JR, Schalper K, Haack H, Silver MR, Nixon C, Bossuyt V, Pusztai L, Lannin DR, Rimm DL.

Cancer Immunol Res. 2015 Apr;3(4):326-32. doi: 10.1158/2326-6066.CIR-14-0133. Epub 2014 Dec 19.

17.

Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic.

Carvajal-Hausdorf DE, Schalper KA, Neumeister VM, Rimm DL.

Lab Invest. 2015 Apr;95(4):385-96. doi: 10.1038/labinvest.2014.157. Epub 2014 Dec 15. Review.

18.

Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.

Juhlin CC, Goh G, Healy JM, Fonseca AL, Scholl UI, Stenman A, Kunstman JW, Brown TC, Overton JD, Mane SM, Nelson-Williams C, Bäckdahl M, Suttorp AC, Haase M, Choi M, Schlessinger J, Rimm DL, Höög A, Prasad ML, Korah R, Larsson C, Lifton RP, Carling T.

J Clin Endocrinol Metab. 2015 Mar;100(3):E493-502. doi: 10.1210/jc.2014-3282. Epub 2014 Dec 9.

PMID:
25490274
19.

Quantitative assessment of miR34a as an independent prognostic marker in breast cancer.

Agarwal S, Hanna J, Sherman ME, Figueroa J, Rimm DL.

Br J Cancer. 2015 Jan 6;112(1):61-8. doi: 10.1038/bjc.2014.573. Epub 2014 Dec 4.

20.

Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time.

Vassilakopoulou M, Parisi F, Siddiqui S, England AM, Zarella ER, Anagnostou V, Kluger Y, Hicks DG, Rimm DL, Neumeister VM.

Lab Invest. 2015 Mar;95(3):334-41. doi: 10.1038/labinvest.2014.139. Epub 2014 Nov 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk